Eli Lilly and Company $LLY Stock: Generali Asset Management SPA SGR Raises Position

Key Points

• Generali Asset Management increased its Eli Lilly position by 6.7% in the third quarter, adding 4,262 shares for a total of 68,033 shares valued at approximately $78.7 million. Institutional investors own 82.53% of the company.
• Eli Lilly reported strong quarterly results and raised its outlook. Revenue increased 39% year over year to $24.4 billion, adjusted EPS reached $7.48 versus a $5.68 consensus estimate, and 2026 revenue guidance rose to $91 billion–$92 billion, driven by Mounjaro and Zepbound demand.
• Analyst sentiment remains bullish, with a consensus “Moderate Buy” rating and a $1,320.25 target price, although investors should monitor pricing pressure, nonrecurring benefits, deal-related charges and potential access concerns for weight-loss drugs.

Generali Asset Management SPA SGR increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 68,033 shares of the company's stock after acquiring an additional 4,262 shares during the period. Eli Lilly and Company comprises 1.4% of Generali Asset Management SPA SGR's portfolio, making the stock its 16th biggest position. Generali Asset Management SPA SGR's holdings in Eli Lilly and Company were worth $78,720,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. IMG Wealth Management Inc. boosted its holdings in shares of Eli Lilly and Company by 30.0% in the third quarter. IMG Wealth Management Inc. now owns 78 shares of the company's stock valued at $90,000 after purchasing an additional 18 shares during the period. Jacobsen Capital Management increased its holdings in Eli Lilly and Company by 0.6% during the 3rd quarter. Jacobsen Capital Management now owns 1,552 shares of the company's stock worth $1,796,000 after purchasing an additional 9 shares during the period. Asset Management One Co. Ltd. increased its holdings in Eli Lilly and Company by 2.2% during the 3rd quarter. Asset Management One Co. Ltd. now owns 393,048 shares of the company's stock worth $454,788,000 after purchasing an additional 8,423 shares during the period. John Boyer Inc. purchased a new position in Eli Lilly and Company during the 3rd quarter worth $72,000. Finally, Lynch Investment Planning LLC bought a new stake in Eli Lilly and Company during the 3rd quarter valued at $142,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LLY. UBS Group set a $1,376.00 target price on Eli Lilly and Company in a report on Friday, August 7th. The Goldman Sachs Group reissued a "buy" rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Truist Financial raised their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Sanford C. Bernstein restated an "outperform" rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a report on Monday. Finally, Morgan Stanley lifted their price objective on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $1,320.25.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and sales beat estimates. Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the roughly $5.68 analyst consensus. Reported EPS was $7.22, up from $6.21 a year earlier. Eli Lilly earnings report
• Positive Sentiment: Demand for GLP-1 drugs continues to accelerate. Mounjaro sales increased 65% to $10.7 billion, while Zepbound revenue climbed 49% to $5.35 billion. The performance reinforced expectations that Lilly can continue gaining share in the rapidly expanding diabetes and obesity markets. Eli Lilly stock jumps on Mounjaro and Zepbound earnings
• Positive Sentiment: Management sharply increased its outlook. Lilly raised 2026 revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The company also highlighted regulatory progress, including Mounjaro’s cardiovascular-risk indication and approval of once-weekly insulin Onswik. Eli Lilly raises revenue outlook
• Positive Sentiment: Pipeline momentum added to investor enthusiasm. Phase 3 data showed experimental retatrutide produced greater A1C reductions and more than double the weight loss of Ozempic 2 mg in adults with type 2 diabetes, strengthening Lilly’s competitive position against Novo Nordisk. Retatrutide trial results
• Neutral Sentiment: Investors should monitor the quality and durability of growth. Realized prices declined about 15%, although a 53% volume increase more than offset the pressure. Approximately $900 million of quarterly benefits came from Jardiance milestones and rebate adjustments, neither of which is expected to recur fully.
• Negative Sentiment: One-time deal-related charges and access concerns remain risks. Lilly recorded about $4.2 billion in acquired in-process R&D charges, while reports also noted a Foundayo sales miss and potential employer concerns about covering costly weight-loss drugs. These factors could pressure margins or slow future demand. Eli Lilly pricing and earnings reaction

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,372.01 on Friday. The firm has a market cap of $1.29 trillion, a price-to-earnings ratio of 46.04, a PEG ratio of 1.73 and a beta of 0.46. The company's 50 day moving average is $1,194.34 and its 200 day moving average is $1,090.89. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52-week low of $812.25 and a 52-week high of $1,408.38.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts' consensus estimates of $5.68 by $1.80. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company's revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $7.02 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 33.22 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.